Caissa Capital Management Ltd. Buys 5,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) major shareholder Caissa Capital Management Ltd. acquired 5,000 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were acquired at an average cost of $2.62 per share, with a total value of $13,100.00. Following the transaction, the insider now owns 1,342,700 shares in the company, valued at $3,517,874. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Caissa Capital Management Ltd. also recently made the following trade(s):

• On Thursday, May 4th, Caissa Capital Management Ltd. bought 15,000 shares of Avalo Therapeutics stock. The stock was acquired at an average cost of $2.79 per share, for a total transaction of $41,850.00.
• On Wednesday, April 26th, Caissa Capital Management Ltd. bought 425 shares of Avalo Therapeutics stock. The shares were bought at an average cost of $2.97 per share, with a total value of $1,262.25.
• On Monday, April 24th, Caissa Capital Management Ltd. purchased 12,500 shares of Avalo Therapeutics stock. The stock was bought at an average cost of $3.06 per share, for a total transaction of $38,250.00.
• On Thursday, April 20th, Caissa Capital Management Ltd. acquired 5,000 shares of Avalo Therapeutics stock. The shares were bought at an average price of $3.08 per share, with a total value of $15,400.00.
• On Monday, April 17th, Caissa Capital Management Ltd. bought 15,000 shares of Avalo Therapeutics stock. The stock was bought at an average price of $2.96 per share, for a total transaction of $44,400.00.
• On Monday, April 10th, Caissa Capital Management Ltd. purchased 31,329 shares of Avalo Therapeutics stock. The shares were purchased at an average price of $2.28 per share, with a total value of $71,430.12.

Avalo Therapeutics Trading Up 1.5 %

Shares of NASDAQ AVTX opened at $2.64 on Tuesday. Avalo Therapeutics, Inc. has a 12-month low of $1.41 and a 12-month high of $7.41. The company has a market cap of $34.85 million, a PE ratio of -0.90 and a beta of 1.63. The stock has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $4.04.

Analysts Set New Price Targets

Separately, Jefferies Financial Group lowered shares of Avalo Therapeutics from a “hold” rating to an “underperform” rating in a research note on Wednesday, February 8th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in shares of Avalo Therapeutics during the second quarter valued at $506,000. Goldman Sachs Group Inc. grew its position in Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company’s stock valued at $324,000 after buying an additional 124,769 shares in the last quarter. Renaissance Technologies LLC increased its stake in Avalo Therapeutics by 819.1% during the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company’s stock valued at $266,000 after buying an additional 327,241 shares during the period. Monashee Investment Management LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth about $105,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth about $95,000. Institutional investors and hedge funds own 67.46% of the company’s stock.

About Avalo Therapeutics

(Get Rating)

Avalo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders.